Scientists at St. Jude Children’s Research Hospital have identified a single gene that acts as a molecular brake on the immune system’s most important cancer-killing cells, and removing that brake dramatically improved the body’s ability to fight tumors and chronic viral infections in mouse models. The gene, called ZMYND8, appears to be a master regulator of CD8-positive T-cell exhaustion, the dysfunctional state that has long frustrated immunologists trying to treat solid tumors. Publishing in the journal Nature, the team led by Hongbo Chi, chair of the St. Jude Department of Immunology, showed that deleting Zmynd8 from T cells not only restored their function on its own but also synergized powerfully with existing immunotherapies, pointing toward a new combination strategy for cancers that currently resist treatment.

CD8-positive T cells are the immune system’s specialized assassins, programmed to recognize and destroy cells that display foreign or abnormal signals on their surfaces, whether those signals come from viruses or from cancerous mutations. Under normal circumstances, these cells mount a vigorous response, proliferating rapidly and releasing toxic molecules that kill infected or malignant targets. But when the stimulation persists for weeks or months, as it does in chronic viral infections and in solid tumors that continuously present antigens, the T cells receive a prolonged barrage of activation signals that pushes them into an overstimulated state. Rather than becoming stronger, they become exhausted: they lose their ability to proliferate, secrete fewer of the cytokines needed to coordinate an attack, and effectively stand down while the tumor or virus continues to progress.

One of the critical signals in this process is interleukin-2, or IL-2, a cytokine that normally fuels T-cell activation and expansion. The St. Jude researchers discovered that exhausted T cells receive suboptimal activation through IL-2 signaling, and that this deficiency is not an accident of the tumor environment but the result of an active genetic program. Their search for the molecular link between chronic overstimulation and exhaustion led them directly to ZMYND8, a protein that normally functions as a transcriptional brake, repressing the expression of certain genes. Among the genes it suppresses is Il2ra, which encodes the IL-2 receptor, the very molecular antenna T cells need to respond to IL-2. In other words, chronic stimulation co-opts ZMYND8 to silence the receptor that would otherwise keep the T cells fighting.

Chi described the significance of the finding in stark terms. “Now we may have a way to overcome CD8-positive T-cell exhaustion and improve their function,” he said in the announcement accompanying the study. “When we deleted Zmynd8, we saw improved CD8-positive T-cell function against tumors and chronic infections, suggesting we may have a new therapeutic target to explore to improve these therapies.” The experiments showed that removing the gene from CD8-positive T cells in mice led to significantly better control of both chronic viral infection and melanoma compared with control animals, demonstrating that the effect holds across two distinct disease contexts that share the same underlying problem of persistent antigen stimulation.

To identify ZMYND8 in the first place, the team employed single-cell CRISPR screening, a technique that allows researchers to systematically knock out individual genes across large populations of cells and observe the consequences in each cell individually. By removing genes involved in regulating gene expression and tracking how T-cell states changed, the scientists could pinpoint which regulators were driving the transition into exhaustion. ZMYND8 stood out from the crowd. “We found that ZMYND8 is a ‘master’ regulator of CD8-positive T-cell exhaustion,” said co-first author Yan Wang, PhD, of the St. Jude Department of Immunology. “Its deletion enhanced effector cell formation, leading to the improved anti-tumor and anti-viral effects we observed.” The term master regulator reflects the gene’s position at a control point that shapes the entire fate of the cell, rather than merely tweaking one downstream pathway.

Having identified the master regulator, the researchers then dissected the mechanism by which it exerts its influence. They found that ZMYND8 physically binds to and suppresses the activity of p300, a well-known transcriptional coactivator that controls the activation of the IL-2 receptor gene. When ZMYND8 is present during chronic stimulation, it clamps down on p300’s ability to drive Il2ra expression, starving the T cell of the IL-2 signaling it needs to maintain its effector identity. “ZMYND8 can transform the chronic antigen stimulation signal that occurs in chronic viral infections and cancer into suppression of IL-2 receptor signaling, leading to an exhausted cell state,” explained co-first author Hao Shi, PhD, also of the St. Jude Department of Immunology. This mechanistic clarity is what elevates the finding beyond a simple correlation: the researchers can now trace a complete pathway from persistent antigen exposure through ZMYND8 recruitment, p300 suppression, IL-2 receptor silencing, and finally the exhausted state itself.

The most clinically exciting results came when the researchers combined Zmynd8 deletion with established immunotherapy approaches. Immune checkpoint blockade, the class of drugs that includes agents targeting PD-1 and CTLA-4, works by releasing a different kind of brake, one that cancers exploit to hide from immune attack. The St. Jude team tested Zmynd8 deletion in CD8-positive T cells alongside checkpoint blockade and separately alongside IL-2 supplementation. In both combinations, they observed an increase in functional effector cells, a corresponding decrease in exhausted cells, and a more profound increase in survival among mice receiving the combined treatments than in mice receiving either intervention alone. “What we’re really excited about is how the combination with immunotherapy enhanced treatment efficacy,” Chi noted, underscoring that the gene deletion did not merely add to the effects of immunotherapy but appeared to multiply them.

The synergy makes biological sense in light of the mechanism. Checkpoint blockade reinvigorates T cells that have already become partially dysfunctional, but if those cells remain unable to respond to IL-2 because ZMYND8 has silenced their receptors, the reinvigoration is incomplete. By removing the ZMYND8 brake, the T cells regain the capacity to receive IL-2 signals, and the checkpoint drugs or IL-2 therapy can then act on cells that are actually equipped to respond. This dual approach addresses both the external brakes that tumors impose and the internal brake that T cells impose on themselves, a combination that may prove essential for solid tumors, which have proven far more resistant to immunotherapy than blood cancers.

The implications for pediatric oncology are particularly significant. Immunotherapy has increased survival for some adults and children with cancer, but its success against many pediatric solid tumors has been limited, in part because T cells in those patients become exhausted before they can clear the disease. A strategy that prevents or reverses exhaustion at the genetic level could expand the population of children who benefit from these treatments. Chi emphasized this translational potential: “We have a new approach that could synergize with immunotherapy. One day, a combination treatment approach could improve survival for patients with solid tumors.”

The study, published in Nature on September 23, 2026, was supported by grants from the National Institutes of Health, including CA253188, AI105887, AI131703, AI140761, AI150241 and AI150514, along with the Cancer Center Support Grant P30 CA021765 and funding from the American Lebanese Syrian Associated Charities, the fundraising and awareness organization of St. Jude. In addition to Chi, Wang and Shi, the research team included Nicole Chapman, Anil KC, Renqiang Sun and Hao Song of St. Jude, and Xiaoxi Meng and Xiang Sun, formerly of the institution. The work represents a growing trend in immunology research: rather than simply boosting immune activation with cytokines or checkpoint inhibitors, scientists are now mapping the intrinsic gene programs that determine whether T cells sustain or surrender their function, and using that map to design interventions that reprogram the cells themselves. If the mouse findings translate to humans, targeting ZMYND8 or the p300-IL-2 receptor axis it controls could become a cornerstone of next-generation cancer immunotherapy.

Subject of Research: The role of the ZMYND8 gene in regulating CD8-positive T-cell exhaustion and its potential as an immunotherapy target

Article Title: Targeting ZMYND8 improves T-cell function and may boost immunotherapy

Article References: Targeting ZMYND8 improves T-cell function and may boost immunotherapy. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: ZMYND8, T-cell exhaustion, CD8-positive T cells, immunotherapy, interleukin-2, p300, checkpoint blockade, St. Jude Children's Research Hospital, solid tumors, chronic viral infection, CRISPR screening, Nature